Print

YOU&I Access Support

Discover a World of Support

The YOU&i™ Support Program is a personalized program that includes information on access and affordability, nurse call support, and resources for patients being treated with IMBRUVICA®.

Your healthcare provider can help you enroll in this program before you start taking IMBRUVICA®. Be sure to ask your doctor, nurse, or office staff about enrolling in the YOU&i™ Support Program at your next appointment.

To learn more about patient enrollment and eligibility, visit youandisupport.com.

  • You can also call 1-877-877-3536, Monday through Friday, 8 am - 8 pm ET
button_enroll_here

Download Enrollment Form

Once enrolled, you may receive:

Access Support

  • Provides you with rapid (2 business days) benefit investigation
  • Provides you information about the prior authorization process
  • Provides you information about insurance appeals process
  • Connects you to a specialty pharmacy
  • YOU&i™ Start Program: If you are experiencing an insurance coverage decision delay, this program may give you access to IMBRUVICA®
    • Eligible patients who have been prescribed IMBRUVICA® for an FDA-approved indication, and who are experiencing an insurance coverage decision delay greater than 5 business days, can receive a free, 30-day supply of IMBRUVICA®
    • If decision delay persists, an additional free, 30-day supply may be provided
    • The free product is offered to eligible patients without any purchase contingency or other obligation

List of Specialty Pharmacies

 

Affordability Support

  • YOU&i™ Instant Savings Program: If you have commercial health insurance and meet eligibility requirements, you will pay no more than $10 per month* for IMBRUVICA®
    • *Month refers to a 30-day supply. Subject to a maximum benefit, 12 months after activation or 12 monthly fills (1-year supply), whichever comes first, unless the maximum dollar benefit has been reached
    • Not valid for patients enrolled in Medicare or Medicaid

    Click here to enroll

  • Foundation Referral: If you need additional financial support, we can provide you information on independent foundations that may be able to provide financial support

Other Resource

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is committed to providing access to medicines for uninsured individuals who lack the financial resources to pay for them. If you need IMBRUVICA® and are uninsured and unable to pay for your medicine, please contact a JJPAF program specialist at 1-800-652-6227 from 9:00 am to 6:00 pm ET, or visit the foundation website at www.jjpaf.org to see if you might qualify for assistance.

Nurse Call Support & Resources

  • Informational phone calls with YOU&i™ Nurses about IMBRUVICA® and your disease
  • Ongoing tips, tools, and other resources sent through mail, e-mail, and text
  • Patient Starter Kits for new IMBRUVICA® patients

Important Safety Information

What should I tell my healthcare provider before taking IMBRUVICA®?

Before you take IMBRUVICA®, tell your healthcare provider about all of your medical conditions, including if you:

  • have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA® for any planned medical, surgical, or dental procedure.
  • have bleeding problems
  • have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high cholesterol, or diabetes
  • have an infection
  • have liver problems
  • are pregnant or plan to become pregnant. IMBRUVICA® can harm your unborn baby. You should not become pregnant while taking IMBRUVICA®.
  • are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will take IMBRUVICA® or breastfeed. You should not do both.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.

How should I take IMBRUVICA®?

  • Take IMBRUVICA® exactly as your healthcare provider tells you to take it.
  • Take IMBRUVICA® 1 time a day.
  • Swallow IMBRUVICA® capsules whole with a glass of water. Do not open, break, or chew IMBRUVICA® capsules.
  • Take IMBRUVICA® at about the same time each day.
  • If you miss a dose of IMBRUVICA® take it as soon as you remember on the same day. Take your next dose of IMBRUVICA® at your regular time on the next day. Do not take 2 doses of IMBRUVICA® on the same day to make up for a missed dose.

What should I avoid while taking IMBRUVICA®?

  • You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) while you are taking IMBRUVICA®. These products may increase the amount of IMBRUVICA® in your blood.

What are the possible side effects of IMBRUVICA®?

IMBRUVICA® may cause serious side effects, including:

  • Bleeding problems can happen during treatment with IMBRUVICA® that can be serious. Tell your healthcare provider if you have any signs of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding or bleeding that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, cough up blood or blood clots, increased bruising, feel dizzy or weak, confusion, change in your speech, or a headache that lasts a long time. Your risk of bleeding may increase if you are also taking a blood thinner medicine.
  • Infections can happen during treatment with IMBRUVICA®. Infections can be serious and may lead to death. Tell your healthcare provider if you have fever, chills, or any other signs or symptoms of an infection while taking IMBRUVICA®.
  • Decrease in blood cell counts. Your healthcare provider should do monthly blood tests to check your blood counts.
  • Heart rhythm problems (atrial fibrillation and atrial flutter). Heart rhythm problems have happened in people treated with IMBRUVICA®, especially in people who have an increased risk for heart disease, have an infection, or who have had heart rhythm problems in the past. Tell your healthcare provider if you get any symptoms of heart rhythm problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, chest discomfort, or you faint.
  • Second primary cancers. New cancers have happened in people who have been treated with IMBRUVICA®, including cancers of the skin or other organs.
  • Kidney Problems. Kidney failure and death have happened in people with MCL receiving IMBRUVICA® treatment.

The most common side effects of IMBRUVICA® in people with chronic lymphocytic leukemia (CLL) include: low blood platelet count, low white blood cell count, diarrhea, low red blood cell count, tiredness, muscle and bone pain, upper respiratory tract infection, rash, nausea, and fever.

The most common side effects of IMBRUVICA® in people with mantle cell lymphoma (MCL) include: low blood platelet count, diarrhea, low white blood cell count, low red blood cell count, tiredness, muscle and bone pain, swelling of legs and feet, upper respiratory tract infection, nausea, bruising, shortness of breath, constipation, rash, stomach (abdomen) pain, vomiting, and decreased appetite. 

Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.

General information about the safe and effective use of IMBRUVICA®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it was not prescribed. Do not give IMBRUVICA® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA® that is written for health professionals.

These are not all the possible side effects of IMBRUVICA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please review the full Important Product Information.

WHAT IS IMBRUVICA®?

IMBRUVICA® is a prescription medicine used to treat people with:

  • Chronic lymphocytic leukemia (CLL) who have received at least one prior treatment
  • Chronic lymphocytic leukemia (CLL) with 17p deletion
  • Mantle cell lymphoma (MCL) who have received at least one prior treatment
    • For MCL IMBRUVICA® is approved on response. Data are not yet available to show if IMBRUVICA® improves survival or symptoms.

It is not known if IMBRUVICA® is safe and effective in children.